No Data
Xi'An International Medical Investment (000516.SZ): The proton therapy system is currently in the precision installation, debugging, and acceptance phase.
On January 3, Gelonghui reported that Xi'An International Medical Investment (000516.SZ) stated on the investor interactive platform that the Xi'An International Medical Investment is constructing a proton therapy center project. Currently, the proton therapy system has entered the precision installation, debugging, and acceptance phase, and it is expected to be completed and put into use by the end of 2025. Additionally, the company still has some land resources awaiting development. In the future, the company will further expand new business sectors such as life health management and integrated medical services based on the existing high-level Medical platform.
Xi'An International Medical Investment (000516.SZ): has cumulatively repurchased 0.49% of its shares.
On January 2, Glorious Group reported that Xi'An International Medical Investment (000516.SZ) announced that as of December 31, 2024, the company had cumulatively repurchased 10,997,100 shares through the Shenzhen Stock Exchange trading system via centralized bidding, accounting for 0.4865% of the company's current total share capital, with a maximum Fill Price of 5.618 yuan/share, a minimum Fill Price of 4.61 yuan/share, and a total transaction amount of 57.4268 million yuan (excluding transaction fees).
Xi'an international medical investment (000516.SZ): The maximum number of inpatient beds at Xi'an High-tech hospital has reached 1,680.
Gelonghui December 4th | Xi'an International Medical Investment (000516.SZ) stated in recent investor relations activities that recently, the maximum daily inpatient bed capacity of Xi'an Gaoxin Hospital has reached 1680 beds; the maximum daily inpatient bed capacity of the North and South campuses of Xi'an International Medical Investment Hospital has reached 3880 beds.
China Merchants Securities: Establishment of prepayment policy for medical insurance funds, releasing incremental signals at the bottom of the pharmaceutical sector.
It is reported that standardized prepayment process management, with the scale of regional prepayment in line with the approved standards for about one month, the prepayment system effectively alleviates the financial pressure of medical institutions, empowering the medical and pharmaceutical industry.
International Medicine: third quarter report 2024
xi'an international medical investment (000516.SZ): a net loss of 0.212 billion yuan in the first three quarters.
GeLongHui on October 24th, xi'an international medical investment (000516.SZ) announced its third-quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 3.606 billion yuan, a year-on-year increase of 7.85%; net income attributable to shareholders of the listed company was a loss of 0.212 billion yuan, a year-on-year increase of 4.59%; net income after deducting non-recurring gains and losses was a loss of 0.22 billion yuan, a year-on-year increase of 37.20%; basic earnings per share was -0.0954 yuan per share.
